Domain Therapeutics

Domain Therapeutics enters into a new collaboration agreement with Pfizer Inc. to profile signaling pathways of GPCRs across multiple diseases

Show more

Domain Therapeutics receives development milestone payment from Merck KGaA, Darmstadt, Germany, for collaboration on adenosine receptor antagonists

Show more
Load more